Kolon Life Science Inc (102940) Fair Value & Analysis
Healthcare · KR · Market cap 422B KRW
Fair value as of: Aug 13, 2026
From 16 valuation models · updated yesterday
Fair value updated Aug 13, 2026, revised from 37,195 KRW to 37,129 KRW (−0.2%) since Jul 20, 2026. Share price −52.4% over the past month.
Below-average quality, screening 101% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (33/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (27,847 KRW). The market is more pessimistic than our downside scenario.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 13,300 KRW – 70,800 KRW · fair‑value band 27,847 KRW – 46,411 KRW · the 18,460 KRW price screens below the 37,129 KRW fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Kolon Life Science Inc (102940) currently trades at 18,460 KRW, while our model-based Fair Value estimate is 37,129 KRW, implying the stock looks roughly 101.1% undervalued today. The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Kolon Life Science Inc generated revenue of 191B KRW at a net margin of -3.0%. Revenue grew 20.2% year over year. Net debt stands at 91.5B KRW. Fundamentals as of Aug 13, 2026
Our scenario range runs from 27,847 KRW (bear case) to 46,411 KRW (bull case); at 18,460 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 75% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at 101%, 102940 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 16 models by family
Widest divergence: Growth Earnings (37,760 KRW) versus Dividend Discount (2,293 KRW). Highest evidence: Residual Income (76).
Notify me when 102940 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 35 · Market factors (momentum, volatility) 15
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain.
Full company description
Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain. The company also provides active pharmaceutical ingredients for anti-cancer and intermediates; and pyrithione antimicrobial for shampoo and soap bars, cosmetic and wet wipes, fabric softeners, metalworking fluids, antifouling paints, and fire-fighters. In addition, it offers Kolon BESFLOC polymer used in chemical, food, leather, pharmaceutical, textile, and dairy industries, as well as in settling reservoirs, sludge thickeners, floating reservoirs, and dehydrators in sewage treatment plants. The company was formerly known as Korea Tissuegene Asia, Ltd. and changed its name to Kolon Life Science Inc. in January 2006. Kolon Life Science Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Kolon Life Science Inc reported revenue of 209B KRW in FY2025 versus 165B KRW in FY2021, a compound +6.0%/yr. Reported net income was 25.0B KRW in FY2025.
Watch 102940: get an alert when its fair value changes →
Peer Group
Pharmaceuticals · 25 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Torrent Pharmaceuticals Limited 500420 | ₹4,876 | ₹4,360 | -11% |
| GlaxoSmithKline Pharmaceuticals Limited 500660 | ₹2,620 | ₹1,452 | -45% |
| Caregen Co 214370 | 64,400 KRW | 7,277 KRW | -89% |
| ST Pharm Co 237690 | 107,000 KRW | 50,110 KRW | -53% |
| Oscotec Inc 039200 | 38,800 KRW | 33,210 KRW | -14% |
| DongKook Pharmaceutical Co 086450 | 21,600 KRW | 31,283 KRW | +45% |
| Huons Global Co 084110 | 25,100 KRW | 58,482 KRW | +133% |
| BINEX Co 053030 | 7,300 KRW | 1,844 KRW | -75% |
| Anterogen.Co.,Ltd., a bio-venture company, 065660 | 15,520 KRW | 4,741 KRW | -69% |
| Kyung Dong Pharmaceutical Co 011040 | 5,180 KRW | 6,165 KRW | +19% |
Compare Kolon Life Science Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Kolon Life Science Inc (102940) overvalued or undervalued?
What is the fair value of 102940?
What is the quality score of 102940?
What is the revenue of Kolon Life Science Inc (102940)?
What is the net profit margin of 102940?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Kolon Life Science Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.